New drug combo before surgery for head and neck cancer
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 70 years old
- Has squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx that is stage III or IVA
- Have not received any prior anti-cancer treatment for this disease
- Good physical condition (able to care for yourself and do light activities)
- Able to have standard surgery plus any needed radiation or chemotherapy afterward
- No active autoimmune disease or other major illnesses
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
This trial tests a new combination treatment for head and neck cancer. The treatment uses an investigational drug (becotatug vedotin) with an immunotherapy (a checkpoint inhibitor). The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.